Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XBIO
- Price
- 2.30
- Stock movement down
- -0.08 (-3.36%)
- Company name
- Xenetic Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 3.55M
- Ent value
- -2.28M
- Price/Sales
- 1.41
- Price/Book
- 0.50
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -51.08%
- 1 year return
- -50.92%
- 3 year return
- -39.33%
- 5 year return
- -21.77%
- 10 year return
- -50.81%
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XBIO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.41 |
| Price to Book | 0.50 |
| EV to Sales | -0.90 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.54M |
| EPS (TTM) | -2.64 |
| FCF per share (TTM) | -1.90 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.52M |
| Gross profit (TTM) | 2.52M |
| Operating income (TTM) | -4.36M |
| Net income (TTM) | -4.08M |
| EPS (TTM) | -2.64 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | -172.82% |
| Profit margin (TTM) | -161.58% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.84M |
| Net receivables | 0.00 |
| Total current assets | 7.03M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 8.05M |
| Accounts payable | 243.34K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.01M |
| Total liabilities | 1.01M |
| Shareholder's equity | 7.04M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.94M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -2.94M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -57.94% |
| Return on Assets | -50.67% |
| Return on Invested Capital | -57.94% |
| Cash Return on Invested Capital | -41.73% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.38 |
| Daily high | 2.38 |
| Daily low | 2.24 |
| Daily Volume | 31K |
| All-time high | 59396.04 |
| 1y analyst estimate | 40.00 |
| Beta | 2.26 |
| EPS (TTM) | -2.64 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| XBIO | S&P500 | |
| Current price drop from All-time high | -100.00% | -12.89% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 11 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -99.07% | -11.07% |
| Avg time to new high | 1311 days | 12 days |
| Max time to new high | 2619 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
3.55M
Marketcap category
Small-cap
Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Jeffrey F. Eisenberg
Country
USA
City
Framingham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page